ProductDescription
SYN115(Tozadenant)isaorally-available,benzothiazole-based,antagoNISToftheAdenosineA2AreceptorforthetreatmentofParkinson"sdiseaseandotherCNS-relatedconditions.SYN115isbeingpursuedasamonotherapyaswellasincombinationwithL-dopamineandisbeingstudiedforitspotentialneuroprotectiveeffects.[1]
AnimalstudieswithSYN115supportbeliefsthatA2AantagonistsreduceParkinson"ssymptomsbyreducingtheinhibitoryoutputofthebasalgangliaindirectpathway.UsingCerebralBloodFlow(CBF)asapharmacodynamicparameter,studieshaveshownthatSYN115inducesasignificantdecreaseinthalamicCBF,consistentwiththedeactivationoftheindirectpathway.[2]
Technicalinformation:
| ChemicalFormula: | C19H26N4O4S | |
| CAS#: | 870070-55-6 | |
| MolecularWeight: | 406.5 | |
| Purity: | >98% | |
| Appearance: | White | |
| ChemicalName: | 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide | |
| Solubility: | Upto50mMinDMSO | |
| Synonyms: | SYN115,SYN-115 |
ShippingCondition:Theproductisshippedinaglassvialatambienttemperature.
Storagecondition:Forlongershelflife,storesolidpowderat4oCdesiccated,orstoreDMSOsolutionat-20oC.
Reference:
| 1. | BiotieTherapieswebsite(2013-04-24) |
| 2. | Blacketal.,QuantificationofIndirectPathwayInhibitionbytheAdenosineA2aAntagonistSYN115inParkinsonDisease.Blacketal.,J.Neurosci.2010,30(48),16284-16292.PubmedID:21123574 |
Cellagen的ChamQ SYBR qPCR预混液（无ROX）| Q321产品描述ChamQSYBR®qPCR预混液（Vazyme，＃Q321）由香槟Taq DNA聚合酶（Vazyme，＃P122）通过抗体修饰的热启动激活技术保护，是专为基于SYBR Green I的定量PCR（qPCR）设计的。ChamQSYBR®qPCR Master Mix的优化缓冲液系统中的独特因素（即促进特异性的Exactor）大大提高了其灵敏度和特异性。该混合物以2倍反应浓度制备，可直接用于鲁棒性低模板qPCR，具有高灵敏度，特异性和可靠性。优点特异性+敏感性的最佳组合。独特的抗体修饰的热启动taq，具有独特的特异性促进因子。Mg2 +和染料的最佳浓度。
